The most dangerous person to ask about tolerability is often the person who doesn’t have to take the drug. Not because they’re unintelligent or without access to data. Not because they’re uncaring, but because they get to go home afterward without the ramifications of the treatment.
The patient does not. The patient takes all the side effects of the drug home. The patient takes it to the dinner table. To the bathroom. To bed. To their child’s soccer game. To the grocery store. To the middle of the night when the rest of the house is sleeping and their body is negotiating with a treatment that is both helping and hurting them.
I have spent enough years living with Stage IV Metastatic Breast Cancer (MBC) to know that there is a profound difference between toxicity reported and toxicity experienced. A profound difference between a side effect listed and a side effect lived. A profound difference between looking at a chart and looking at your own reflection in the mirror and wondering if this version of survival is sustainable.
Medicine loves categories: Grade 1, Grade 2, Grade 3. Manageable. Acceptable. Tolerable. The words look so neat on paper. Life rarely does.
A physician might document diarrhea. A patient may quietly stop leaving the house, purchase adult diapers and ensure that a chance of clothes is always within reach. A researcher might document fatigue. A mother may stop volunteering at school because she no longer has enough energy to get through the day. A trial report might state that most adverse events were low grade. A patient may spend every waking hour calculating whether the treatment is worth what it is taking from them.
The problem isn’t the data. The problem is believing the data tells the whole story. It doesn’t. It can’t. Suffering does not always fit neatly into a checkbox and patients are not always reliable narrators of their own suffering.
I know that statement may make some people uncomfortable. But it is true. Patients with terminal cancer become experts at minimizing. Not because we are dishonest, because we are desperate. We understand the stakes. We understand that there may not be another drug waiting behind this one. We understand that a dose reduction might happen leading to a treatment interruption. A discontinuation.
We understand that progression is not an abstract concept discussed at conferences. Progression is personal. Progression is our life. Progression will lead to our death. So we adapt. We normalize. We rationalize.
We say, “It’s not that bad.” Even when it is.
We say, “I can handle it.” Even when we’re barely handling it.
We say, “The fatigue is manageable.” Because manageable has become a relative term.
When the alternative is cancer growing, almost anything becomes manageable. That is the dirty little secret nobody talks about when discussing tolerability: the willingness to endure suffering is not evidence that suffering does not exist.
Read that again.
The willingness to endure suffering is not evidence that suffering does not exist.
Patients living with terminal cancer are constantly making impossible calculations. Would I trade diarrhea for tumor shrinkage? Would I trade exhaustion for stability? Would I trade neuropathy for another year? Would I trade nausea for another Christmas? Another birthday? Another ordinary Tuesday?
The answer is often yes. But yes does not mean easy. Yes does not mean acceptable. Yes does not mean well tolerated. It means we made the calculation and decided the benefit outweighed the cost. For us. At that moment in our lives.
Those are very different things.
This is why I struggle when people who have never swallowed the pills, sat through the infusions, or lived inside the side effects begin speaking confidently about tolerability. You can discuss efficacy. You can discuss response rates. You can discuss progression-free survival. You can discuss toxicity data.
But tolerability belongs to the people carrying the treatment in their bodies.
Tolerability is not a statistic. It is an experience and experiences are messy. They are contradictory. A treatment can save your life and diminish your quality of life simultaneously. A drug can be miraculous and miserable. A patient can be grateful and suffering at the same time. Those truths coexist every day.
What I appreciated most about the recent call to stop minimizing toxicity in oncology is that it recognizes something patients have known all along. Language matters. Words matter. Calling something “manageable” does not make it manageable. Calling something “well tolerated” does not make it well tolerated.
And patient-reported outcomes, while incredibly important, do not solve the problem entirely, because there is always a gap between what can be measured and what can be lived. A questionnaire captures a moment, but a life unfolds between questionnaires. The form records the symptom, but the patient carries the consequence. The spreadsheet captures the event while the patient absorbs the cost.
For those of us living with incurable disease, that cost-benefit analysis is ongoing. Relentless. Personal. Intimate. Which is why I think humility is required whenever we talk about tolerability.
Perhaps the most honest statement isn’t that a drug is well tolerated. Perhaps the most honest statement is that some patients decide the benefit is worth enduring the toxicity. That language leaves room for reality. It leaves room for complexity. It leaves room for the patient.
And after all these years, I’ve become convinced that the patient is the one voice that should never be treated as an afterthought in conversations about tolerability. Because at the end of the day, when the conference ends, when the paper is published, when the presentation slides are closed and the audience goes home, the patient remains.
Living with the consequences. Living with the benefits. Living with the tradeoffs. Living with the treatment.
And that lived experience deserves more than a grade, a checkbox, or a declaration that something was “well tolerated.” It deserves to be heard.
